This is a working overview of Synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
=== Self-service grocery stores === The concept of a self-service grocery store predates the supermarket; it was developed by entrepreneur Clarence Saunders at his Piggly Wiggly stores, the first of which opened in 1916. Saunders was awarded several patents for the ideas he incorporated into his stores. The stores were a financial success and Saunders began to offer franchises. The general trend since then has been to stock shelves at night so that customers, the following day, can obtain their own goods and bring them to the front of the store to pay for them. Although there is a higher risk of shoplifting, the costs of appropriate security measures ideally will be outweighed by reduced labor costs.
According to a study published in 2017, the odds of contracting CJD for patients in Japan who received a Lyodura graft was at least 1 in 877 (~0.1%). In 2004, five Australian patients had been diagnosed with Creutzfeldt–Jakob disease after receiving Lyodura grafts. Due to the long latent period of Creutzfeldt–Jakob disease, epidemiologists remain uncertain how many people will be affected by the disease. B.Braun Melsungen and several other entities agreed to compensate the families of Japanese CJD victims for more than $600,000 each. An award-winning documentary was produced on the subject. The Canadian Broadcasting Corporation's The Fifth Estate segment, "Deadly Harvest", dealt with the product's history, sale in Canada, and health effects worldwide. The product has since been banned for use in Canada.
== Further reading == Cape Colony House of Assembly (1881). Copies of all Correspondence and Telegrams Having Reference to the Recent Rebellion. Saul Solomon & Co. Retrieved 7 January 2022. Lagden, Godfrey (1910). The Basutos: The Mountaineers & Their Country. Vol. II. Appleton. OCLC 908824713. Retrieved 7 January 2022. Sanders, Peter (2011). Throwing Down White Man: Cape Rule and Misrule in Colonial Lesotho, 1871–1884. Merlin Press. ISBN 978-0-850-36654-9. Tylden, G. (1969). "Basutoland Roll of Honour 1851 – 1881". Journal of the Society for Army Historical Research. 1 (5). ISSN 0026-4016. Retrieved 7 January 2022.
Researchers at Bristol-Myers Squibb found that increased steric bulk of the N-terminal amino acid side-chain led to increased stability. To additionally increase stability the trans-rotamer was stabilized with a cis-4,5-methano substitution of the pyrrolidine ring, resulting in an intramolecular van-der-Waals interaction, thus preventing intramolecular cyclisation. Because of that increased stability, the researchers continued their investigation on cis-4,5-methano cyanopyrrolidines and came across with a new adamantyl derivative, which showed extraordinary ex vivo DPP-4 inhibition in rat plasma. Also noted, high microsomal turnover rate which indicated that the derivative was quickly converted to an active metabolite. After hydroxylation on the adamantyl group they had a product with better microsomal stability and improved chemical stability. That product was named saxagliptin (Onglyza) (Figure 6). In June 2008 AstraZeneca and Bristol-Myers Squibb submitted a new drug application for Onglyza in the United States and a marketing authorization application in Europe. Approval was granted in the United States by the FDA in July 2009 for Onglyza 5 mg and Onglyza 2.5 mg. This was later combined with extended-release metformin (taken once daily) and approved by the FDA in January 2011 under the trade name Kombiglyze XR.
On 3 September 2021, the Supreme Court of Justice ruled that the president can serve two consecutive terms in office. The ruling overturned a 2014 ruling that presidents had to wait ten years to be eligible to run for re-election. Constitutional lawyers criticized the ruling, saying that consecutive re-election violates El Salvador's constitution. The 2021 ruling allowed Bukele to run for re-election in the 2024 presidential election. ARENA and the FMLN protested the court's ruling, with an ARENA spokesperson calling it a "precursor to a dictatorship" and an FMLN representative saying that the state is serving only one person: Bukele. The ruling was also condemned by the United States government. Jean Elizabeth Manes, chargé d'affaires of the United States to El Salvador, called it "clearly contrary to the Salvadoran constitution". According to Manes, the ruling was a direct result of the May 2021 legislative replacement of the Supreme Court justices.
Sources: en.wikipedia.org
On 3 December, Hezbollah fired two projectiles at the Shebaa Farms in what it described as a "defensive and warning response", accusing Israel of committing repeated ceasefire violations. In response, the IDF conducted a wave of strikes in southern Lebanon, killing nine people. Two people, including a Lebanese security services corporal, were killed by Israeli strikes earlier that day. On 9 December, four reservists of the 35th Paratroopers Brigade were killed in an accident when unmarked munitions exploded in a tunnel in the Labbouneh area, which detonated Hezbollah weaponry, leading to the tunnel's collapse. The IDF withdrew from Al-Khiyam on 12 December in accordance with the ceasefire. On 26 January 2025, a day before the ceasefire's deadline, Israeli forces fired at Lebanese residents en route to communities near the border, killing 22 people and injuring 124. After the ceasefire's initial deadline passed on 27 January, Israeli troops refused to withdraw from southern Lebanon, accusing the Lebanese government of not upholding the deal. The ceasefire was extended to 18 February. On 13 February, the IDF accused Iran's Quds Force of smuggling cash onto civilian flights en route to Beirut–Rafic Hariri International Airport to fund Hezbollah. In response, Lebanon blocked an Iranian passenger plane from entering its territory. The decision sparked protests from Hezbollah supporters, who blocked access to the airport, and on 15 February, attacked a UNIFIL convoy en route to the airport, injuring deputy force commander Chok Bahadur Dhakal.
The renin–angiotensin–aldosterone system is a major blood pressure regulating mechanism. Markers of electrolyte and water imbalance in the body such as hypotension, low distal tubule sodium concentration, decreased blood volume and high sympathetic tone trigger the release of the enzyme renin from the cells of juxtaglomerular apparatus in the kidney. Renin activates a circulating liver derived prohormone angiotensinogen by proteolytic cleavage of all but its first ten amino acid residues known as angiotensin I. ACE (angiotensin converting enzyme) then removes a further two residues, converting angiotensin I into angiotensin II. ACE is found in the pulmonary circulation and in the endothelium of many blood vessels. The system increases blood pressure by increasing the amount of salt and water the body retains. Angiotensin II is also a potent vasoconstrictor.
During barcode sequencing, high molecular weight DNA samples that contain the targeted DNA sequence, ranging from fifty to several hundred kilobases in size, are combined with gel beads containing unique barcodes, enzymes, and sequencing reagents. Microfluidic device can partition input DNA molecules into individual nanoliter-sized droplets of water-in-oil emulsion, called GEMs. Each GEM contains gel beads coated with the same barcode and primers, and a small amount of DNA. The primers are complementary to specific regions of the DNA molecule, allowing for amplification of the DNA in the droplets through PCR. The barcodes enable the identification and grouping of sequencing reads that originate from the same long fragment, which is crucial for downstream analysis.
Serum, suspected to contain IgE antibodies, is drawn from the allergic (atopic) patient. This serum is injected intradermally into a non-allergic person. The suspected antigens are then intradermally injected into the non-allergic person 24–48 hours later. If the person being tested for an allergy has made antibodies for the antigen, this will cause a local reaction in the non-allergic person when the antibodies mix with the antigen. This demonstrates a type I hypersensitivity reaction, and the allergic reaction to the injected antigen is confirmed for the patient being tested. A positive PK test usually appears as a wheal and flare. The test was developed by Otto Prausnitz and Heinz Küstner. The first PK test occurred in 1921 when Prausnitz injected Küstner's serum into his abdominal skin. Küstner had previously noted that he developed allergic symptoms after eating fish. After eating some fish, Prausnitz's skin became hot, red, and swollen at the site of the serum injection, confirming their hypothesis that Küstner was allergic to fish.
Sources: en.wikipedia.org
40. Pain Physician. 2026 Sep;29(6):E751. Comment on "Cervical Erector Spinae Plane Block vs. Epidural Steroid Injection for Cervical Radicular Pain: A Clinical Trial". Sacaklidir GY(1), Sacaklidir R(2). Author information: (1)Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey. (2)Sisli Hamidiye Etfal Training and Research Hospital, Department of Physical Medicine and Rehabilitation, Pain Management Section, Istanbul, Turkey.
=== Radioactivity === Thorium was first observed to be radioactive in 1898, by the German chemist Gerhard Carl Schmidt and later that year, independently, by the Polish-French physicist Marie Curie. It was the second element that was found to be radioactive, after the 1896 discovery of radioactivity in uranium by French physicist Henri Becquerel. Starting from 1899, the New Zealand physicist Ernest Rutherford and the American electrical engineer Robert Bowie Owens studied the radiation from thorium; initial observations showed that it varied significantly. It was determined that these variations came from a short-lived gaseous daughter of thorium, which they found to be a new element. This element is now named radon, the only one of the rare radioelements to be discovered in nature as a daughter of thorium rather than uranium. After accounting for the contribution of radon, Rutherford, now working with the British physicist Frederick Soddy, showed how thorium decayed at a fixed rate over time into a series of other elements in work dating from 1900 to 1903. This observation led to the identification of the half-life as one of the outcomes of the alpha particle experiments that led to the disintegration theory of radioactivity. The biological effect of radiation was discovered in 1903. The newly discovered phenomenon of radioactivity excited scientists and the general public alike. In the 1920s, thorium's radioactivity was promoted as a cure for rheumatism, diabetes, and sexual impotence.
== Mechanism of action == Buformin delays absorption of glucose from the gastrointestinal tract, increases insulin sensitivity and glucose uptake into cells, and inhibits synthesis of glucose by the liver. Buformin and the other biguanides are not hypoglycemic, but rather antihyperglycemic agents. They do not produce hypoglycemia; instead, they reduce basal and postprandial hyperglycemia in diabetics. Biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels.
Sources: pubmed.ncbi.nlm.nih.gov
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.